Table 2.

Characteristics of Gene Expression Profile Tests for breast cancer.

	Number of Genes	Information Provided	Indication
MammaPrint® /BluePrint®	70/80	Risk of distant recurrence (5 and 10 years), with or without benefit of chemotherapy	Pre- and post-menopausal
			Early stage
			Tumor up to ~5 cm
		Identification of intrinsic molecular subtypes, information about tumor behavior, long-term prognosis and response to systemic therapy	ER+/ER−
			HER2+/HER2−
			LN− or LN+ (up to 3 LN+)
Oncotype DX®	21	Prediction of cancer recurrence in 10 years assuming 5 years of endocrine therapy	Pre- and post-menopausal
			Early stage
			ER+
			HER2−
			LN− or LN+ (up to 3 LN+)
Prosigna®	50	Cancer subtype, risk stratification, prediction of 10 years distant recurrence-free survival assuming 5 years of endocrine therapy	Post-menopausal
			Early stage
			ER+
			HER2−
			LN− or LN+ (up to 3 LN+)
Endopredict®	12	Risk of distant recurrence (10 years), probability of distant recurrence (5–15 years) after diagnosis, estimated absolute benefit of chemotherapy at 10 years	Pre- and post-menopausal
			Early stage
			ER+
			HER2−
			LN− or LN+ (up to 3 LN+)
Breast Cancer Index®	7	Risk of general (0 to 10 years) and late (5 to 10 years) distant recurrence, predicts benefit of extended endocrine therapy in early stage HR+ breast cancer	Post-menopausal
			Early stage
			ER+
			HER2−
			LN− or LN+ (up to 3 LN+)

ER: estrogen receptor; LN: lymph node; HR: hormone receptor.